chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Anaphylaxis, transfer to hospital via ambulance Within 5 minutes of vaccine, flushed, nausea, weak, dizzy, blood pressure drop Treated with epi, benadryl im, glucagon and zofran
Bad rash on his chest, stomach, privates, back; This is a spontaneous report from a contactable consumer, the patient. A 12-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0185) via an unspecified route of administration in the right arm on 18May2021 at 13:15 as a single dose for COVID-19 immunisation. Medical history included central processing auditory disorder and COVID-19. The patient had no known allergies to medications, food or other products. The patient did not receive any concomitant medications. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 20May2021 at 16:00, 2 days after the vaccination, the patient experienced bad rash on his chest, stomach, privates, back. The event resulted in doctor or other healthcare professional office/clinic visit. No therapeutic measures were taken as a result of the reported events. The clinical outcome of bad rash on his chest, stomach, privates, back was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Patient received dose 1 3/5/21 and dose 2 4/2/2021. Became ill early July 2021 with a stuffy nose and sinus infection. On 7/3 returned to PCP and was diagnosed with Covid infection at a different facility per report. On 7/15/21, following admission  to  ICU on 7/14/21, patient tested positive for sars-cov2.
4/01/2022 at 1108 Employee called COVID-19 Vaccine Nurse Support Line to report symptoms post COVID-19 booster vaccine. Vaccine Name - Pfizer Vaccine Date - 3/29/2022  Booster Dose - Yes Location - Left Deltoid Date of Symptom Onset ? 3/29/2022 Symptoms ? Extreme Tiredness, Headache, Feverish (Last on 3/30/22), Achiness Last Day of Work and Shift ? Schedule: M-F (9a-5p) / Missed Work: Today, 3/30/22 & 3/31/22 Home Remedies ? N/A (Did Want to Mask Symptoms In Case They Worsened and Didn't Take Anything) Any Improvement ? Somewhat Improved (Able to Return to Work today, 4/01/22)
Pain on site (lasting 6+hours), nausea! (2 days), headache!  (3 days),  lightheaded, dizzy, shaky hands, tiredness (2 days), chills, fever (low grade of 99.1* for 1 day),  minimal swelling, no significant bruising,  muscle pain and soreness (7 days)
This spontaneous report was received from a physician via company representative and refers to a patient of unknown age and gender. The patient's pertinent medical history, concurrent conditions, drug reactions or allergies were not reported. On 11-FEB-2016, the patient was vaccinated with an improperly stored dose of PEDVAXHIB Single Dose Vaccine, 10-pack, lot number K004541, expiration date 04-DEC-2016, (dose, route and anatomical location were not reported). The improperly stored PEDVAXHIB was in a Refrigerator, and, the highest temperature of excursion was 47 Fahrenheit degrees (8.33 Celsius degrees) with a sum of 24 hours of excursion. No adverse effects were reported and no product quality complain was involved. This is one of several reports from the same reporter. Additional information has been requested.
She is 17 years old, date of birth 3july2003; where she got the shot looked like a massive mosquito bite/big red ring about 4.5 inches in diameter; area was itchy; area was swollen; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE ERYTHEMA (where she got the shot looked like a massive mosquito bite/big red ring about 4.5 inches in diameter), VACCINATION SITE PRURITUS (area was itchy), VACCINATION SITE SWELLING (area was swollen) and PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (She is 17 years old) in a 17-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. unknown) for COVID-19 vaccination.     No Medical History information was reported.    On 18-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In March 2021, the patient experienced VACCINATION SITE ERYTHEMA (where she got the shot looked like a massive mosquito bite/big red ring about 4.5 inches in diameter), VACCINATION SITE PRURITUS (area was itchy) and VACCINATION SITE SWELLING (area was swollen). On 18-Mar-2021, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (She is 17 years old, date of birth 3july2003). On 18-Mar-2021, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (She is 17 years old) had resolved. On 30-Mar-2021, VACCINATION SITE SWELLING (area was swollen) had resolved. At the time of the report, VACCINATION SITE ERYTHEMA (where she got the shot looked like a massive mosquito bite/big red ring about 4.5 inches in diameter) had not resolved and VACCINATION SITE PRURITUS (area was itchy) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       This case was linked to MOD21-065676 (E2B Linked Report).; Sender's Comments:  MOD21-065676:crosslink
10 minutes after receiving the MMR vaccine he walked to the front desk with his mother, he sneezed 5 times with mucus coming out of his nose, he then had a gagging cough and threw up once, he then continued to have dry heaves and he looked puffy around his eyes, he then started to become lethargic alternating with combative, his O2 dropped to 88%, he face became puffier, we give him AUVI-Q 0.15 in the left thigh and called 911, oxygen was started as his O2 was 100%, he was lethargic off and on, but his HR, RR and BP remained stable, he never developed a rash, he was taken by ambulance to the local hospital and given IV SOLU-MEDROL and diphenhydramine, after about 4 hours he became much more active, less swollen and he was drinking, he was discharged home from the ER with a EPIPEN, he will follow up with an allergist; the clinical picture was consistent with anaphylaxis.
Information has been received from an office manager regarding to a current 16 year old patient (gender not reported). No medical history, concurrent conditions nor concomitant medications were reported. On 05-JUL-2018, the patient was vaccinated with a dose of PROQUAD (lot number and expiration date not reported), subcutaneous for prophylaxis. On 16-JAN-2019, the patient received another dose of PROQUAD (lot number and expiration date not reported), subcutaneous for prophylaxis. No known adverse effects were reported.
Rt arm where varicella was given w/ red/edema area of 1 1/2-2. Client stated that area itches. Advise to treat sym. Given BENADRYL out to area and if size increases or blister appears to call office.
A report has been received from a Pharmacist concerning a 45 year old, Male subject, who had been receiving Nasal FLUMIST QUADRIVALENT (Intranasal). FLUMIST QUADRIVALENT (Intranasal) started on 03-Dec-2013. The patient was administered expired FLUMIST on 03-Dec-2013. The outcome of the event of administration of expired FLUMIST is unknown. The report was considered to be non-serious.
pt recvd vax; burning in lungs; burning in throat; difficulty swallowing, malaise, swollen tongue w/ lumps;
Employee Health office received word from the employee's manager that the employee was taken to the Emergency Room with facial drooping and inability to blink approximately 24 hrs after receiving flu vaccine. Manager verbalized the employee was diagnosed with having Bell's Palsy. Manager disclosed that employee has been complaining of ringing in the ears for past couple weeks and had an MRI already scheduled with her PCP prior to onset of Bell's Palsy symptoms. Manager reports the ED physician does not think the incident is vaccine related, rather coincidental.
Pt. reports had a firm area at injection site. By 9 pm on 10-25-05. Pt went to bed, awoke at 3 am vomited one time, returned to bed. Upon awakening noted red firm area at injection site. Examined pt at the office (1320) 10/26 area 6 cm x 5cm reddened, indurated.
TINGLING IN RIGHT ARM; BURNING DURING INJECTION; This spontaneous report received from a patient concerned a 77 year old female. The patient's weight, height, and medical history were not reported.  The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 180531, and expiry: unknown) dose was not reported, administered on 15-MAR-2021 16:30 on right arm for prophylactic vaccination. No concomitant medications were reported.  On 15-MAR-2021, the subject experienced tingling in right arm. On 15-MAR-2021, the subject experienced burning during injection. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from tingling in right arm, and burning during injection on 15-MAR-2021. This report was non-serious.
Exhaustion, sore hips, skin felt like it hurt to touch, sleeplessness during evening because of being uncomfortable, slept all day following day and felt out of it. Could not sleep comfortably following night either. Very strong arm pain. Two days later itchy injection site and very red. Felt better by 10 AM on the second day after shot.
Difficulty breathing, stridor about 30 minutes after vaccine,  Pt received albuterol treatment, solumedrol  and benadryl IV.   Pt's respiratory status improved
Leg and hip weakness, Swelling of leg and feet. Acking legs, cramping legs and feet. Shortness of breath, eyes not focusing
Swab test came back detected but in the reference it came back not detected; Had a positive exposure at work; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of EXPOSURE TO SARS-COV-2 (Had a positive exposure at work) and SUSPECTED COVID-19 (Swab test came back detected but in the reference it came back not detected) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007B21A) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No medical history reported).    On 07-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 07-Apr-2021, the patient experienced EXPOSURE TO SARS-COV-2 (Had a positive exposure at work). On 12-Apr-2021, the patient experienced SUSPECTED COVID-19 (Swab test came back detected but in the reference it came back not detected). At the time of the report, EXPOSURE TO SARS-COV-2 (Had a positive exposure at work) and SUSPECTED COVID-19 (Swab test came back detected but in the reference it came back not detected) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Relevant concomitant medications were not reported.  Treatment information was not provided.
Severe, shooting neuropathy pain in feet and up back of legs began within 6 hours of receiving vaccine and lasted for  approximately 26 hours.  One small area of shingles appeared on the lower left side of back at approximately the 36 hour mark.  The neuropathy pain was unlike anything experienced before.
about 8 hr post-vaccine, awakened with severe headache, nausea, muscle pain & pain at injection site; took Naproxen (2) & 2.5 mg Zomig for relief of headache.  1 am - Naproxen repeated; headache continued for 3 days.
c/o whole lt.arm ached, denies any redness or red streaking, no swelling. c/o severe generalized body aches, with shakey chills and sweating. Temp. 101.4 that evening. c/o was in bed the next 2 days., continued with rigors, sweating and body aches and fever. Denied any rash or hives., no N or V.
Strong allergic reaction:  breakout of skin throughout most of body, boils, legions.
Information has been received from a CMA concerning a 9 year old pt who on 04/14/03 was vaccinated with a first dose of pneumococcal vaccine 23 polyvalent (Lot #643783/0709M). Within the first 24 hours post vaccination, the pt developed a site reaction that was 3x5 inches in diameter, red and patchy, slightly swollen, and warm to the touch. Unspecified medical attention was sought and the pt was treated with a dexamethasone dose pack. No product quality complaint was noted. It was also reported that the pt's 12 year old brother was vaccinated with a first dose of pneumococcal vaccine 23 polyvalent (Lot # 643783/0709M) and also developed a site reaction (WAES #0305USA01027).  Follow up information revealed that there was "no further information to offer in this case". No additional information is expected.
This spontaneous case, initially received from other health professional (Pharmacist) on 29-Nov-2017, concerning a 58-year-old, adult, female patient. On 15-Oct-2017, the patient was administered with AFLURIA trivalent (dose: 0.5 ml, route of administration: intramuscular, anatomical location: deltoid, batch no: XT30006 and expiry date: 07-Jun-2018). On 20-Oct-2017, the patient noticed a dot at the vaccination site. It was reported that the dot is red and was radiating (reported as growing). The patient consulted a physician and was diagnosed with granuloma annulare. The patient was prescribed with unspecified steroid cream but had no improvement. At the time of this report, the patient had recovered from the event granuloma annulare and the event injection site redness was not resolved. The reporter assessed this case as non-serious. Significant case correction received with IRD 29-Nov-2017: The "description to be coded" term was changed from 'injection site dentation' to 'injection site redness'. Follow-up received on 17-Jan-2018: It was reported that, the patient was not previously vaccinated, and the vaccine was administered on 15-Oct-2017. The patient was diagnosed with granuloma annulare and it had resolved on an unspecified date. Narrative was amended accordingly.
pain in arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (pain in arm) in a 43-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 002C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 20-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 20-Apr-2021, the patient experienced PAIN IN EXTREMITY (pain in arm). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. On 27-Apr-2021, PAIN IN EXTREMITY (pain in arm) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication were provided.   This case was linked to MOD-2021-142026 (Patient Link).
This spontaneous report as received from a medical assistant refers to an unspecified number of patients of unknown age and gender. The patients' medical history, concurrent conditions and concomitant medications were not reported. On unknown dates, the patients were vaccinated with the improperly stored (in 51.3 F for 30,75 hours and in 59.4 F for 4,5 hours) doses of RECOMBIVAX HB (lot # M020926, expiration date 11-AUG-2018; dose and route of administration were not reported) for prophylaxis. No adverse effect and no previous excursion were reported. The call was made because of the data logger. This is one of several reports received from the same reporter. Follow up information has been received on 13-DEC-2016. All telephone attempts to obtain follow-up information have been unsuccessful. Additional information has been requested. Narrative updated. Sender's Comments: US-009507513-1611USA001105: US-009507513-1610USA011275: US-009507513-1611USA001102: US-009507513-1611USA001103: MERCK 1611USA001104:Mfr number.
Hospitalized, She was in the hospital 9 days later for 5 days; It will be about 6 months after 1st,It has been 6 months and she wants to get the second dose; This spontaneous case was reported by a consumer and describes the occurrence of HOSPITALISATION (Hospitalized, She was in the hospital 9 days later for 5 days) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013MZOA) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Rheumatoid arthritis (The patient has rheumatoid arthritis since she was a child, for almost 60 years now.).    On 03-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Feb-2021, the patient experienced HOSPITALISATION (Hospitalized, She was in the hospital 9 days later for 5 days) (seriousness criterion hospitalization). On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (It will be about 6 months after 1st,It has been 6 months and she wants to get the second dose). The patient was hospitalized from 12-Feb-2021 to 17-Feb-2021 due to HOSPITALISATION. On 17-Feb-2021, HOSPITALISATION (Hospitalized, She was in the hospital 9 days later for 5 days) had resolved. At the time of the report, PRODUCT DOSE OMISSION ISSUE (It will be about 6 months after 1st,It has been 6 months and she wants to get the second dose) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication information was provided by the reporter. No treatment information was provided by the reporter. Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded. Very limited information has been reported at this time. Further information is not expected.   Most recent FOLLOW-UP information incorporated above includes: On 22-Jul-2021: Non significant follow up-address, phone number added; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded. Very limited information has been reported at this time. Further information is not expected.
APPROXIMATELY 2 DAYS AFTER VACINE SHOT MY FAIR STARTED TO FALL OUT VERY AGGRESSIVELY THAN EVER BEFORE. PRIOR TO THIS EVENT, MY HAIR WAS NOT FALLING OUT.
No additional adverse event; the patient received the 4th dose of PEDVAXHIB that was expired; the patient received the 4th dose of PEDVAXHIB; This spontaneous report was received from a nurse practitioner, via company representative, regarding a 15-month-old male patient. The patient's pertinent medical history, concurrent conditions, concomitant medications and previous drug reactions/allergies were not reported.  On 26-FEB-2020, the patient was vaccinated with the fourth dosage of an expired haemophilus b conjugate vaccine (meningococcal protein conjugate) (LIQUID PEDVAXHIB) (strength, dose and route of administration were not reported; lot number N034005 was verified to be valid for haemophilus b conjugate vaccine (meningococcal protein conjugate), expiration date was on 31-JAN-2020) as prophylaxis (expired product administered and incorrect dose administered). No additional adverse events were reported.
Patient received Moderna COVID vaccine on 1/25/21 (lot # 042L20A), 2/23/21 (lot # 002A21A), and 9/3/21 (lot # 062E21A). On 2/10/22, patient tested positive for COVID at Medical. On 2/11/22, patient admitted to our inpatient facility with COVID pneumonia and acute right side heart failure. As of today (2/14/22), patient is still admitted in our med/surg unit.
Initial unsolicited report received from physician on 18-SEP-2017 and additional information also received on 18-Sep-2017. This case involves a four-year-old male patient who was vaccinated with 0.5 ml dose of FLUZONE (frequency once, batch number: U4698CB, expiration date: 30 Jun 2014, dose and site of administration was not reported) via intramuscular route on 25-Sep-2013. The patient's medical history and concomitant medications were not reported. On an unknown day, within 15 minutes following the vaccination, the patient experienced flushing, severe abdominal pain, wheezing, copious amount of nasal drainage. On an unspecified date, post vaccination, the patient experienced anaphylaxis due to gelatin content. Lab data was not reported. The patient received corrective treatment with epinephrine and given prednisone. On an unknown date, the patient recovered from events while patient was at office and patient was able to return home. This case was considered as serious due to medically significant events. List of documents held by sender: none. Sender's Comments: Patient experience anaphylaxis to INFLUENZA USP TRIVAL A-B SUBVIRION NO PRESERVATIVE VACCINE due to gelatin content. Time to onset is compatible. Anaphylaxis can cause by medication, insect bite, any exposure to chemical and also Information such as patient medical history, concomitant medication, and adverse reactions to previous vaccinations, is needed to further assess this case. Based on available information role of vaccine cannot be excluded.
0-14 hours: pain at injection site but no other notable symptoms.  14-18 hours: headache, muscle aches, joint aches, fatigue, increasing pain at injection site (without swelling or redness at injection site)  18-30 hours: headache, joint, and muscle aches, fatigue, with severe pain at injection site, fever of 99.6, chills, drenching sweating, puffy eyes, rash on torso and legs.  30-48 hours: all previous symptoms except puffy eyes and rash reduced with benadryl  48-60 hours: all previous symptoms. Fever increased to 100.4 F, Puffy eyes and rash returned more severe. Took benadryl and they reduced in severity.  60 hours: reduction in all symptoms. No more fever. Pain in arm reduced from severe to very mild (only noticeable if palpated). Only remaining symptom is fatigue.
Burning pain in left arm. Numbness left face, arm and lower extremity. Pain in wrist and ankle swelling.
Vaccine expired on 4/27/23 and was administered on 5/5/23.
Swollen lymph node under left arm and left side of neck, both are very large 3 - 5 inches in size
My mother experienced fatigue, headache, arm pain, nausea, loss of appetite and passed away two days after second dose of Covid-19 Pfizer vaccine.   *Please note: Hospital has patient listed with a 7/4/1945 birth date which was incorrect and never corrected. Birth certificate shows 7/5/1945 as correct date of birth.
Overcome with exhaustion suddenly, hot & cold, severe stabbing pain in armpit when laying down, headache in strange places in my head I felt better by morning, took 2 aspirin at 4am. I don't seem to have any appetite today, otherwise I feel OK.
Patient describes having fever, tremors and extreme fatigue after getting shingrix vaccine for 1-2 days. Patient stated onset was that evening. Patient called ambulance, but they did not transport him to hospital. Patient then recovered after approx 2 days.